TIL · Instil Bio, Inc. · Fails to Deliver
$6.95
-0.27 (-3.74%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 13, 2026
The latest filing states the doubt was alleviated.
“As discussed above and in Note 10 to the accompanying condensed consolidated financial statements, the 2024 Loan is due in January 2027, for total principal of $85.6 million, which is in excess of cash, cash equivalents, and marketable securities on hand as of June 30, 2026, which we concluded is an indicator of substantial doubt about our ability to continue as a going concern. We concluded that management's plans, including Complex Therapeutics LLC's contractual right to exercise the extension option to January 2028, which is within Complex Therapeutics LLC's control, alleviate the conditions that raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$48.63M
Shares
6.78M
Volume · Oct 5
12.94K
Avg daily vol (3M)
11.8K
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-09-09 | 1 | $7.82 | $8 |
| 2026-09-08 | 79 | $7.58 | $599 |
| 2026-08-12 | 4 | $7.49 | $30 |
| 2026-07-30 | 270 | $7.22 | $1,949 |
| 2026-07-20 | 407 | $7.42 | $3,020 |
| 2026-07-17 | 472 | $7.51 | $3,545 |
| 2026-07-15 | 1,167 | $7.82 | $9,126 |
| 2026-07-14 | 3 | $7.64 | $23 |
| 2026-07-06 | 769 | $7.73 | $5,944 |
Showing 1–9 of 9 settlements